Article Text

Download PDFPDF
Amniotic membrane-covered bio-onlays for treatment of ocular surface disease
  1. C Cursiefen1,
  2. C Rummelt1,
  3. M W Beckmann2,
  4. F E Kruse3
  1. 1Department of Ophthalmology, Friedrich-Alexander University, Erlangen-Nuremberg, Erlangen, Germany
  2. 2Department of Gynaecology, Friedrich-Alexander University, Erlangen-Nuremberg, Erlangen, Germany
  3. 3Department of Ophthalmology, Friedrich-Alexander University, Erlangen-Nuremberg, Erlangen, Germany
  1. Correspondence to: Dr C Cursiefen Department of Ophthalmology, Friedrich-Alexander University, Erlangen-Nuremberg, Schwabachanlage 6,91054 Erlangen, Germany; claus.cursiefen{at}augen.imed.uni-erlangen.de

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Amniotic membrane (AM) transplantation has been used successfully for the treatment of ocular surface diseases for several years.1–3 Indications for use of AM at the cornea include persistent epithelial defects, corneal ulcers and chemical burns.1–3 Surgical strategies for AM placement onto the cornea are suturing AM onto the corneal surface (“patch”), into a corneal defect (“graft”) or a combination of both strategies (“sandwich”).1–5

All published reports for use of AM in patients are based on the use of sutures. Although most patients can be treated with the suture-based approach, there are several situations in which sutures should be avoided: patients under intensive care, long-lasting corneal epithelial defects causing a cornea too thin to support sutures or sutures may be technically difficult to place in the case of a previous graft, and, in addition, sutures can induce scarring and neovascularisation.6 Since the beneficial effects of AM are at least partially mediated by agents released from AM and by AM acting as a natural bandage contact lens,1–5 we reasoned …

View Full Text

Footnotes

  • Funding: Interdisciplinary Center for Clinical Research (IZKF) Erlangen (A9), ELAN Fonds (AZ: 05.06.04.1).

  • Competing interests: None declared.